Quantum BioPharma Expands PR and Investor Relations Strategy with New Agency Partnerships

Quantum BioPharma Ltd. (NASDAQ: QNTM) has strategically positioned itself for increased market visibility by engaging two specialized firms to lead its public relations and investor awareness campaigns. Enterprise Canada Inc. has been retained indefinitely to develop the company's comprehensive media strategy, while Empire Market Ventures, LLC will focus on targeted investor marketing and outreach for a three-month period beginning February 7, 2025.

The communications initiative coincides with significant progress in the company's product development portfolio. Key products include unbuzzd™, a rapid alcohol detoxification beverage slated for Q1 2025 availability, rekvry™, an alcohol misuse treatment, and LUCID-21-302, a potential multiple sclerosis treatment advancing toward Phase 2 clinical trials.

These strategic partnerships suggest Quantum BioPharma is actively working to increase market awareness and investor interest in its innovative biotech solutions. The company's focus on neurodegenerative and metabolic disorders, particularly its lead compound Lucid-MS, which has shown promise in preventing and reversing myelin degradation in preclinical models, represents a potentially significant advancement in medical treatment.

The company's diversified approach includes maintaining a 25.71% ownership stake in Celly Nutrition Corp., the spinoff company for the over-the-counter version of unbuzzd™. This arrangement includes a royalty structure that could generate substantial future revenue, with payments of 7% of sales until reaching $250 million, after which the royalty will decrease to 3% in perpetuity.

By investing in strategic communications and maintaining a robust product development pipeline, Quantum BioPharma appears positioned to enhance its visibility in the competitive biopharmaceutical landscape.